Abstract: This disclosure describes novel 15-deoxy-16-hydroxy-16-substituted prostanoic acids and congeners thereof having utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion.

Abstract: This disclosure describes 11-deoxy-11-substituted members of the E.sub.2, F.sub.2, E.sub.1, F.sub.1, dihydro E.sub.1 and dihydro F.sub.1 prostaglandin series which are useful as hypotensive agents and as anti-ulcer agents.

Abstract: This disclosure describes novel 15-deoxy-16-hydroxy-16- substituted prostanoic acids and congeners thereof having utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion, and particularly, alkyl esters, such as the methyl ester, of such acids.

Abstract: This disclosure describes novel 15-deoxy-16-hydroxy-16-substituted prostanoic acids and congeners thereof having utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion.

Abstract: Vinylstannyl derivatives and the processes for their conversion to vinyliodides, vinylbromides and vinyllithium reagents. The vinylstannyl, vinyliodides, vinylbromide derivatives and vinyllithiums are useful as intermediates for the preparation of prostaglandin analogs.

Abstract: This disclosure describes 11-deoxy-11-substituted members of the E.sub.2, F.sub.2, E.sub.1, F.sub.1, dihydro E.sub.1 and dihydro F.sub.1 prostaglandin series which are useful as hypotensive agents and as anti-ulcer agents.

Abstract: This disclosure describes novel 15-deoxy-16-hydroxy-16-substituted prostanoic acids and congeners thereof having utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion.

Abstract: This disclosure describes novel 16-aryloxy-17,18,19,20-tetranoprostanoic acids and derivatives thereof useful as bronchodilators and as hypotensive and contraceptive agents.

Abstract: Alkenylzirconium reagents of the general structural formula IX, ##STR1## are useful in the syntheses of prostaglandin analogs. In the preceding structural formula J is bromo or chloro, R.sub.1 is hydrogen, methyl, ethyl, vinyl, 1-propenyl, or cyclopropyl, R.sub.4 is alkyl of 2-7 carbon atoms, and R.sub.3 is a protecting group such as tetrahydropyranyl, 1-ethoxyethyl, or C.sub.1 -C.sub.4 -trialkylsilyl.

Abstract: This disclosure describes certain 6,9.alpha.-epoxy prostacyclines and their intermediates. These compounds are useful as bronchodilators and inflammatory mediator release inhibitors.

Abstract: This disclosure describes novel 16-aryloxy-17,18,19,20-tetranorprostanoic acids and derivatives thereof useful as bronchodilators and as hypotensive and contraceptive agents.

Abstract: This disclosure describes novel 15-deoxy-16-hydroxy-16- substituted prostanoic acids and congeners thereof having utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion, and particularly, alkyl esters, such as the methyl ester, of such acids.

Abstract: This disclosure describes novel 15-deoxy-16-hydroxy-16-substituted prostanoic acids and congeners thereof having utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion.

Abstract: This disclosure describes novel 15-deoxy-16-hydroxy-16-substituted prostanoic acids and congeners thereof having utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion.

Abstract: This disclosure describes certain 6,9.alpha.-epoxy prostacyclines and their intermediates. These compounds are useful as bronchodilators.

Abstract: The invention described herein relates to novel 15-deoxy-16-hydroxy-16-ethynyl or 16-(1-propynyl) prostaglandins of E, F, D and A series having on the terminal methylene carbon of the alpha chain a substituent selected from the group consisting of: ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen and C.sub.1 -C.sub.6 alkyl; R.sub.15 is selected from the group consisting of C.sub.1 -C.sub.4 alkyl, di-C.sub.1 -C.sub.4 -alkylamino, phenyl and phenyl substituted with one or more substituents selected from the group consisting of C.sub.1 -C.sub.4 alkyl, OR, SR, F or Cl, wherein R is an alkyl group.

Abstract: This disclosure describes 11-deoxy-11-substituted members of the E.sub.2, F.sub.2, E.sub.1, F.sub.1, dihydro E.sub.1 and dihydro F.sub.1 prostaglandin series which are useful as hypotensive agents and as anti-ulcer agents.

Abstract: 15-Deoxy-16-hydroxy-16-ethynyl and 16-ethynylsubstituted prostanoic acids and congeners thereof, useful as bronchodilators, hypotensive agents, and as agents for the control of excessive gastric secretion.

Abstract: 15-Deoxy-16-hydroxy-16-ethynyl and 16-ethynylsubstituted prostanoic acids and congeners thereof, useful as bronchodilators, hypotensive agents, and as agents for the control of excessive gastric secretion.

Abstract: This disclosure describes esters having prostaglandin-like activity of 15-deoxy-16-hydroxy-16-substituted-prostanoic acids formed by replacing the hydroxy group of the C.sub.1 -carboxylic acid substituent with para-acetamidophenoxy, methylsulfonylamido, para-acetylphenoxy, para-phenylphenoxy, C.sub.3 -C.sub.10 cycloalkoxy, arylalkoxy wherein the alkoxy group has from 7-12 carbon atoms, phenoxy or phenoxy substituted with 1-3 chlorine atoms or C.sub.1 -C.sub.3 alkyl, phenacyloxy or phenacyloxy ring-substituted with from 1-3 bromine atoms, a nitro moiety, C.sub.1-C.sub.8 arylalkyl, or arylalkoxy wherein the alkoxy group has from 7-12 carbon atoms; substituted arylamino (C.sub.1 -C.sub.12), substituted-naphthoxy, fluorenoxy, carboxyalkoxy (C.sub.5 -C.sub.